EcoDrugPlus

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSVVUG00000016249
Gene Symbol: HTR3A
3 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSVVUG00000016234
Gene Symbol: HTR3B
3 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 3d

Ensembl ID : ENSVVUG00000007131
Gene Symbol: HTR3D
1 Cross references
57 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSVVUG00000014538
Gene Symbol: HTR4
3 Cross references
200 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSVVUG00000002770
Gene Symbol: HTR5A
3 Cross references
210 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSVVUG00000021785
Gene Symbol: HTR7
1 Cross references
219 Possible Orthologues:

60s Acidic Ribosomal Protein P1

Ensembl ID : ENSVVUG00000012023
Gene Symbol: LOC112915613
3 Cross references
147 Possible Orthologues:

60s Ribosomal Protein L21

Ensembl ID : ENSVVUG00000009183
Gene Symbol: LOC112910771
3 Cross references
151 Possible Orthologues:

60s Ribosomal Protein L23a

Ensembl ID : ENSVVUG00000000587
Gene Symbol: LOC112935166
3 Cross references
51 Possible Orthologues:

60s Ribosomal Protein L30-Like

Ensembl ID : ENSVVUG00000007668
Gene Symbol: LOC112917826
3 Cross references
122 Possible Orthologues:

60s Ribosomal Protein L38-Like

Ensembl ID : ENSVVUG00000023863
Gene Symbol: LOC112917684
2 Cross references
62 Possible Orthologues:

60s Ribosomal Protein L39

Ensembl ID : ENSVVUG00000004075
Gene Symbol: LOC112922044
3 Cross references
66 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).